Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Cruise worker 'murders newborn son on board ship': Shocked co
Norwegian Cruise Line, Wix.com rise; Cushman & Wakefield, Target fall, Monday, 5/20/2024
China's first intelligent offshore drilling platform installed
Nina Dobrev hospitalized with a neck brace due to serious e
Flight attendant reveals why plane passengers should NEVER fall asleep before take off
Who is Abi Carter? Inside the American Idol winner's unconventional family life
BBC Countryfile star Adam Henson's wife wrote heartbreaking goodbye letters after cancer diagnosis
Rays opening day starter Zach Eflin placed on 15
Celebrity birthdays for the week of May 26
Company wins court ruling to continue development of Michigan factory serving EV industry
Benedict Cumberbatch looks suave as he joins his co